B
고바이오랩
348150KOSDAQ자연과학 및 공학 연구개발업55.3 / 100
Reference Date: 2026-06-10
Financial Score20.0 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 26.5% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
KobioLab is a global biotech company leading the development of microbiome-based therapeutics, with a diverse pipeline targeting immune, metabolic, and neurological disorders. Utilizing its proprietary Smartiome platform, the company is conducting global clinical trials and has expanded into the functional food market through its subsidiary, Wibiome.
Number of Employees
57people
Average Salary
57.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 62.704.0Point
PBR
1.42Industry Average 3.247.0Point
Half of industry avg (excellent)
ROE
-13.31Industry Average -32.093.5Point
Well below industry avg
Debt Ratio
58.16Industry Average 7.310.0Point
8.0x industry avg (risky)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲53.8% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲11.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -13.5% (improving, 3yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85
- Positive"아토피 피부염 치료 신약…셀트리온과 기술이전 논의"
고바이오랩의 아토피 피부염 치료 신약 기술이전 논의로 인해 긍정적인 시장 반응 예상.
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 3,605Won52-week high 6,93052-week low 3,605
1-month return0.0Point
1m -26.50% (strong drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral분기보고서 (2026.03)2026-05-14